Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Long-Term Debt Repayments (2016 - 2020)

Champions Oncology has reported Long-Term Debt Repayments over the past 6 years, most recently at -$16000.0 for Q2 2020.

  • Quarterly results put Long-Term Debt Repayments at -$16000.0 for Q2 2020, down 107.66% from a year ago — trailing twelve months through Apr 2020 was $35000.0 (down 86.64% YoY), and the annual figure for FY2020 was $35000.0, down 86.64%.
  • Long-Term Debt Repayments for Q2 2020 was -$16000.0 at Champions Oncology, down from $37000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for CSBR hit a ceiling of $209000.0 in Q2 2019 and a floor of -$16000.0 in Q2 2020.
  • Median Long-Term Debt Repayments over the past 5 years was $6500.0 (2016), compared with a mean of $19944.4.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 3383.33% in 2019 and later tumbled 107.66% in 2020.
  • Champions Oncology's Long-Term Debt Repayments stood at $6000.0 in 2016, then changed by 0.0% to $6000.0 in 2017, then surged by 450.0% to $33000.0 in 2018, then tumbled by 78.79% to $7000.0 in 2019, then crashed by 328.57% to -$16000.0 in 2020.
  • The last three reported values for Long-Term Debt Repayments were -$16000.0 (Q2 2020), $37000.0 (Q1 2020), and $7000.0 (Q4 2019) per Business Quant data.